Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy

Scott R. Solomon, Andrew St. Martin, Nirav N. Shah, Giancarlo Fatobene, Monzr M. Al Malki, Karen K. Ballen, Asad Bashey, Nelli Bejanyan, Javier Bolaños Meade, Claudio G. Brunstein,

Blood Advances · 2019 · 45 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

Key Points Disease-free survival is higher with myeloablative regimens for patients in their third to fifth decade. Beyond the fifth decade, low-dose total body irradiation regimens offset mortality associated with transplant procedure.

References

29